Phyllis Awor
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Phyllis Awor has a total of 143 co-authors. Here are the top co-authors by number of shared publications:
- Manuel W. Hetzel
Swiss Tropical and Public Health Institute, Allschwil, Switzerland
13 shared publications - Aita Signorell
Swiss Tropical and Public Health Institute
12 shared publications - Nina C. Brunner
Swiss Tropical and Public Health Institute, Allschwil, Switzerland
11 shared publications - Christian Burri
Department of Medicine, Swiss Tropical and Public Health Institute, Allschwil, Switzerland
10 shared publications - Christian Lengeler
Swiss Tropical and Public Health Institute, Allschwil, Switzerland
10 shared publications - Giulia Delvento
Swiss Tropical and Public Health Institute
8 shared publications
Latest Publications
- 20 January 2026
- Published by Edward Elgar Publishing
- p. 396-417
Promoting social innovation for the Sustainable Development Goals: the role of higher education institutions in Africa
- 20 January 2026
- Published by Edward Elgar Publishing
- p. 396-417
Promoting social innovation for the Sustainable Development Goals: the role of higher education institutions in Africa
- Open Access
- 1 January 2025
- Published by BMJ in BMJ Innovations
- Vol. 11 (1) , 5-14
Gender-based violence and associated factors in communities in Uganda: data from the social innovation in health initiative
Background: Addressing gender-based violence (GBV) requires a contextual understanding of its associated factors. The purpose of the study was to determine the prevalence and factors associated with GBV among beneficiaries of social innovation health projects in Uganda, inorder to inform the programmes. Methods: This was a cross-sectional study with 500 participants from five social innovation projects addressing gender and health in Uganda. Modified Poisson regression analysis with robust standard errors was used for inferential statistics. Results: Lifetime prevalence of sexual violence was 23.3% among women and 2.9% among men. The prevalence of physical violence within the last 12 months was higher among women (23.7%), compared with men (7.7%). Women engaged in subsistence farming (prevalence ratio (PR)=1.12; 95% CI 1.01 to 1.24); (PR=1.19; 95% CI 1.06 to 1.33) and those from households where men alone made decisions about major household purchases (PR=1.18; 95% CI 1.05 to 1.33); (PR=1.19; 95% CI 1.05 to 1.34) were more likely to experience sexual violence and physical violence, respectively. Women having a disability (PR=1.20; 95% CI 1.03 to 1.39) were also more likely to experience physical violence. Conversely, women whose husbands were involved in domestic work were less likely to experience sexual violence (PR=0.84; 95% CI 0.78 to 0.90) and physical violence (PR=0.83; 95% CI 0.76 to 0.91). Conclusion: There was high prevalence of sexual and physical violence, among women in the studied population. There is a need to strengthen and scale up targeted interventions and policies to address the identified burden and risk factors and to promote gender equality, as is undertaken by the social innovation projects described in this study.
- 1 January 2025
- Published by BMJ in BMJ Innovations
- Vol. 11 (1) , 5-14
Open AccessGender-based violence and associated factors in communities in Uganda: data from the social innovation in health initiative
Background: Addressing gender-based violence (GBV) requires a contextual understanding of its associated factors. The purpose of the study was to determine the prevalence and factors associated with GBV among beneficiaries of social innovation health projects in Uganda, inorder to inform the programmes. Methods: This was a cross-sectional study with 500 participants from five social innovation projects addressing gender and health in Uganda. Modified Poisson regression analysis with robust standard errors was used for inferential statistics. Results: Lifetime prevalence of sexual violence was 23.3% among women and 2.9% among men. The prevalence of physical violence within the last 12 months was higher among women (23.7%), compared with men (7.7%). Women engaged in subsistence farming (prevalence ratio (PR)=1.12; 95% CI 1.01 to 1.24); (PR=1.19; 95% CI 1.06 to 1.33) and those from households where men alone made decisions about major household purchases (PR=1.18; 95% CI 1.05 to 1.33); (PR=1.19; 95% CI 1.05 to 1.34) were more likely to experience sexual violence and physical violence, respectively. Women having a disability (PR=1.20; 95% CI 1.03 to 1.39) were also more likely to experience physical violence. Conversely, women whose husbands were involved in domestic work were less likely to experience sexual violence (PR=0.84; 95% CI 0.78 to 0.90) and physical violence (PR=0.83; 95% CI 0.76 to 0.91). Conclusion: There was high prevalence of sexual and physical violence, among women in the studied population. There is a need to strengthen and scale up targeted interventions and policies to address the identified burden and risk factors and to promote gender equality, as is undertaken by the social innovation projects described in this study.
- Open Access
- 1 January 2025
- Published by BMJ in BMJ Innovations
- Vol. 11 (1) , 1-4
Why does an intersectional gender approach matter for social innovations in health?
- 1 January 2025
- Published by BMJ in BMJ Innovations
- Vol. 11 (1) , 1-4
Open AccessWhy does an intersectional gender approach matter for social innovations in health?
- Open Access
- 1 January 2025
- Published by BMJ in BMJ Innovations
- Vol. 11 (1) , 64-69
Exploring gender and intersecting social stratifiers at a community level: insights from three social innovation research hubs in Colombia, the Philippines and Uganda
Background: Social innovations have been recognised as potential interventions to address health disparities, particularly in low- and middle-income countries. In the context of social innovation research, understanding how gender intersects with other social stratifiers is crucial, as these intersections are shaped by power imbalances and systems and structures of oppression, influencing health vulnerability, access to services and treatment outcomes. Prompted by the Intersectional Gender Research Strategy set up by the Special Programme for Research and Training in Tropical Diseases (TDR), three hubs of the Social Innovation in Health Initiative aimed to explore how gender dimensions played a role in existing social innovation projects at a community level.Methods: We purposefully conducted the research in selected areas where social innovations in health were operating—sites in Colombia, the Philippines and Uganda. Qualitative methods, including semistructured interviews and focus group discussions, were used to gather in-depth insights. An iterative, inductive process of open coding guided the analysis, allowing themes to emerge organically and ensuring findings were grounded and contextually relevant.Results: The following insights were drawn: (a) vulnerability and disease exposure stem from deeply ingrained patriarchal societal structures wherein social innovations operate; (b) gender norms and gender roles influence the participation in social innovations and health programmes; (c) The lack of women’s autonomy and gender-based discrimination remains a crucial challenge in the achievement of equitable health and (d) social innovations in health recognise the unique challenges faced by women and girls and respond by designing tailor-fit interventions to address these specific needs.Conclusion: Incorporating an intersectional gender lens can lead to a deeper, more nuanced understanding of the relationship between social innovations in health and the communities that they operate in.
- 1 January 2025
- Published by BMJ in BMJ Innovations
- Vol. 11 (1) , 64-69
Open AccessExploring gender and intersecting social stratifiers at a community level: insights from three social innovation research hubs in Colombia, the Philippines and Uganda
Background: Social innovations have been recognised as potential interventions to address health disparities, particularly in low- and middle-income countries. In the context of social innovation research, understanding how gender intersects with other social stratifiers is crucial, as these intersections are shaped by power imbalances and systems and structures of oppression, influencing health vulnerability, access to services and treatment outcomes. Prompted by the Intersectional Gender Research Strategy set up by the Special Programme for Research and Training in Tropical Diseases (TDR), three hubs of the Social Innovation in Health Initiative aimed to explore how gender dimensions played a role in existing social innovation projects at a community level.Methods: We purposefully conducted the research in selected areas where social innovations in health were operating—sites in Colombia, the Philippines and Uganda. Qualitative methods, including semistructured interviews and focus group discussions, were used to gather in-depth insights. An iterative, inductive process of open coding guided the analysis, allowing themes to emerge organically and ensuring findings were grounded and contextually relevant.Results: The following insights were drawn: (a) vulnerability and disease exposure stem from deeply ingrained patriarchal societal structures wherein social innovations operate; (b) gender norms and gender roles influence the participation in social innovations and health programmes; (c) The lack of women’s autonomy and gender-based discrimination remains a crucial challenge in the achievement of equitable health and (d) social innovations in health recognise the unique challenges faced by women and girls and respond by designing tailor-fit interventions to address these specific needs.Conclusion: Incorporating an intersectional gender lens can lead to a deeper, more nuanced understanding of the relationship between social innovations in health and the communities that they operate in.
- 7 August 2024
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 68 (8) , e0165923
Indigenous emergence and spread of kelch13 C469Y artemisinin-resistant Plasmodium falciparum in Uganda
Artemisinin-based combination therapies (ACTs) were introduced as the standard of care for uncomplicated malaria in Africa almost two decades ago. Recent studies in East Africa have reported a gradual increase in kelch13 ( k13 ) mutant parasites associated with reduced artesunate efficacy. As part of the Community Access to Rectal Artesunate for Malaria project, we collected blood samples from 697 children with signs of severe malaria in northern Uganda between 2018 and 2020, before and after the introduction of rectal artesunate (RAS) in 2019. K13 polymorphisms were assessed, and parasite editing and phenotyping were performed to assess the impact of mutations on parasite resistance. Whole-genome sequencing was performed, and haplotype networks were constructed to determine the geographic origin of k13 mutations. Of the 697 children, 540 were positive for Plasmodium falciparum malaria by PCR and were treated with either RAS or injectable artesunate monotherapy followed in most cases by ACT. The most common k13 mutation was C469Y (6.7%), which was detected more frequently in samples collected after RAS introduction. Genome editing confirmed reduced in vitro susceptibility to artemisinin in C469Y-harboring parasites compared to wild-type controls ( P < 0.001). The haplotypic network showed that flanking regions of the C469Y mutation shared the same African genetic background, suggesting a single and indigenous origin of the mutation. Our data provide evidence of selection for the artemisinin-resistant C469Y mutation. The realistic threat of multiresistant parasites emerging in Africa should encourage careful monitoring of the efficacy of artemisinin derivatives and strict adherence to ACT treatment regimens.
- 7 August 2024
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 68 (8) , e0165923
Indigenous emergence and spread of kelch13 C469Y artemisinin-resistant Plasmodium falciparum in Uganda
Artemisinin-based combination therapies (ACTs) were introduced as the standard of care for uncomplicated malaria in Africa almost two decades ago. Recent studies in East Africa have reported a gradual increase in kelch13 ( k13 ) mutant parasites associated with reduced artesunate efficacy. As part of the Community Access to Rectal Artesunate for Malaria project, we collected blood samples from 697 children with signs of severe malaria in northern Uganda between 2018 and 2020, before and after the introduction of rectal artesunate (RAS) in 2019. K13 polymorphisms were assessed, and parasite editing and phenotyping were performed to assess the impact of mutations on parasite resistance. Whole-genome sequencing was performed, and haplotype networks were constructed to determine the geographic origin of k13 mutations. Of the 697 children, 540 were positive for Plasmodium falciparum malaria by PCR and were treated with either RAS or injectable artesunate monotherapy followed in most cases by ACT. The most common k13 mutation was C469Y (6.7%), which was detected more frequently in samples collected after RAS introduction. Genome editing confirmed reduced in vitro susceptibility to artemisinin in C469Y-harboring parasites compared to wild-type controls ( P < 0.001). The haplotypic network showed that flanking regions of the C469Y mutation shared the same African genetic background, suggesting a single and indigenous origin of the mutation. Our data provide evidence of selection for the artemisinin-resistant C469Y mutation. The realistic threat of multiresistant parasites emerging in Africa should encourage careful monitoring of the efficacy of artemisinin derivatives and strict adherence to ACT treatment regimens.
- Open Access
- 23 December 2023
- Published by BMJ in BMJ Public Health
- Vol. 1 (1) , e000088
Delivering maternal and child health interventions through the private sector in LMIC: a scoping review of strategies and effective approaches
Despite growing evidence on the role of private health providers, the global public health response to date has primarily focused on the provision of public sector health services for women and children in low and middle-income countries (LMIC). Limitations of this approach are well documented and include shortage of human resources, inefficient institutional frameworks and inadequate quality especially in rural areas. In order to achieve universal health coverage, it is important to strengthen both the public and private sectors. The objective was to determine effective strategies for engagement with private health providers for maternal and child health in LMIC. A scoping review of both published and grey literature from 2000 to 2023 was undertaken, including papers reporting on either population-level data on the extent of utilisation of the private sector for maternal and child health services in more than one country; or interventions for service provision in the private sector using population-level results in one or more country; or both of the above. PubMed, Embase and Web of Science databases were searched, 362 full-text articles were reviewed and 43 studies were included in the synthesis. Aggregate results were extracted, and content analysis was used to identify engagement strategies/themes. The results confirm that the private sector is the dominant provider of outpatient care for women and children in LMIC, and a significant provider of reproductive and maternal health services including for inpatient care. Effective strategies and recommendations for engagement with private health providers are presented across challenges of private health provider engagement.
- 23 December 2023
- Published by BMJ in BMJ Public Health
- Vol. 1 (1) , e000088
Open AccessDelivering maternal and child health interventions through the private sector in LMIC: a scoping review of strategies and effective approaches
Despite growing evidence on the role of private health providers, the global public health response to date has primarily focused on the provision of public sector health services for women and children in low and middle-income countries (LMIC). Limitations of this approach are well documented and include shortage of human resources, inefficient institutional frameworks and inadequate quality especially in rural areas. In order to achieve universal health coverage, it is important to strengthen both the public and private sectors. The objective was to determine effective strategies for engagement with private health providers for maternal and child health in LMIC. A scoping review of both published and grey literature from 2000 to 2023 was undertaken, including papers reporting on either population-level data on the extent of utilisation of the private sector for maternal and child health services in more than one country; or interventions for service provision in the private sector using population-level results in one or more country; or both of the above. PubMed, Embase and Web of Science databases were searched, 362 full-text articles were reviewed and 43 studies were included in the synthesis. Aggregate results were extracted, and content analysis was used to identify engagement strategies/themes. The results confirm that the private sector is the dominant provider of outpatient care for women and children in LMIC, and a significant provider of reproductive and maternal health services including for inpatient care. Effective strategies and recommendations for engagement with private health providers are presented across challenges of private health provider engagement.
- Open Access
- 5 July 2023
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 3 (7) , e0001949
Starting at the community: Treatment-seeking pathways of children with suspected severe malaria in Uganda
Community health workers (CHW) usually refer children with suspected severe malaria to the nearest public health facility or a designated public referral health facility (RHF). Caregivers do not always follow this recommendation. This study aimed at identifying post-referral treatment-seeking pathways that lead to appropriate antimalarial treatment for children less than five years with suspected severe malaria. An observational study in Uganda enrolled children below five years presenting to CHWs with signs of severe malaria. Children were followed up 28 days after enrolment to assess their condition and treatment-seeking history, including referral advice and provision of antimalarial treatment from visited providers. Of 2211 children included in the analysis, 96% visited a second provider after attending a CHW. The majority of CHWs recommended caregivers to take their child to a designated RHF (65%); however, only 59% followed this recommendation. Many children were brought to a private clinic (33%), even though CHWs rarely recommended this type of provider (3%). Children who were brought to a private clinic were more likely to receive an injection than children brought to a RHF (78% vs 51%, p<0.001) and more likely to receive the second or third-line injectable antimalarial (artemether: 22% vs. 2%, p<0.001, quinine: 12% vs. 3%, p<0.001). Children who only went to non-RHF providers were less likely to receive an artemisinin-based combination therapy (ACT) than children who attended a RHF (odds ratio [OR] = 0.64, 95% CI 0.51–0.79, p<0.001). Children who did not go to any provider after seeing a CHW were the least likely to receive an ACT (OR = 0.21, 95% CI 0.14–0.34, p<0.001). Health policies should recognise local treatment-seeking practices and ensure adequate quality of care at the various public and private sector providers where caregivers of children with suspected severe malaria actually seek care.
- 5 July 2023
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 3 (7) , e0001949
Open AccessStarting at the community: Treatment-seeking pathways of children with suspected severe malaria in Uganda
Community health workers (CHW) usually refer children with suspected severe malaria to the nearest public health facility or a designated public referral health facility (RHF). Caregivers do not always follow this recommendation. This study aimed at identifying post-referral treatment-seeking pathways that lead to appropriate antimalarial treatment for children less than five years with suspected severe malaria. An observational study in Uganda enrolled children below five years presenting to CHWs with signs of severe malaria. Children were followed up 28 days after enrolment to assess their condition and treatment-seeking history, including referral advice and provision of antimalarial treatment from visited providers. Of 2211 children included in the analysis, 96% visited a second provider after attending a CHW. The majority of CHWs recommended caregivers to take their child to a designated RHF (65%); however, only 59% followed this recommendation. Many children were brought to a private clinic (33%), even though CHWs rarely recommended this type of provider (3%). Children who were brought to a private clinic were more likely to receive an injection than children brought to a RHF (78% vs 51%, p<0.001) and more likely to receive the second or third-line injectable antimalarial (artemether: 22% vs. 2%, p<0.001, quinine: 12% vs. 3%, p<0.001). Children who only went to non-RHF providers were less likely to receive an artemisinin-based combination therapy (ACT) than children who attended a RHF (odds ratio [OR] = 0.64, 95% CI 0.51–0.79, p<0.001). Children who did not go to any provider after seeing a CHW were the least likely to receive an ACT (OR = 0.21, 95% CI 0.14–0.34, p<0.001). Health policies should recognise local treatment-seeking practices and ensure adequate quality of care at the various public and private sector providers where caregivers of children with suspected severe malaria actually seek care.
- Open Access
Delivering maternal and child health interventions through the private sector in LMIC: a scoping review of strategies and effective approaches
Despite growing evidence on the role of private health providers, the global public health response to date has primarily focused on the provision of public sector health services for women and children in low and middle income countries (LMIC). Limitations of this approach are well documented and include: shortage of human resources, inefficient institutional frameworks and inadequate quality especially in rural areas. In order to achieve Universal Health Coverage, it is important to strengthen both the public and private sector. The objective was to determine effective strategies for engagement with private health providers for maternal and child health in LMIC. A scoping review of both published and grey literature from 2000 – 2022 was undertaken, using including all types of papers reporting on: either population level data on the extent of utilization of the private sector for maternal and child health services in more than one country; or interventions for service provision in the private sector using population level results in one or more country; Or both of the above. Aggregate results were extracted, and content analysis was used to identify engagement strategies/themes. The results confirm that the private sector is the dominant provider of outpatient care for women and children in LMIC, and a significant provider of reproductive and maternal health services including for inpatient care. Effective strategies and recommendations for engagement with private health providers are presented across challenges of private health provider engagement.
Open AccessDelivering maternal and child health interventions through the private sector in LMIC: a scoping review of strategies and effective approaches
Despite growing evidence on the role of private health providers, the global public health response to date has primarily focused on the provision of public sector health services for women and children in low and middle income countries (LMIC). Limitations of this approach are well documented and include: shortage of human resources, inefficient institutional frameworks and inadequate quality especially in rural areas. In order to achieve Universal Health Coverage, it is important to strengthen both the public and private sector. The objective was to determine effective strategies for engagement with private health providers for maternal and child health in LMIC. A scoping review of both published and grey literature from 2000 – 2022 was undertaken, using including all types of papers reporting on: either population level data on the extent of utilization of the private sector for maternal and child health services in more than one country; or interventions for service provision in the private sector using population level results in one or more country; Or both of the above. Aggregate results were extracted, and content analysis was used to identify engagement strategies/themes. The results confirm that the private sector is the dominant provider of outpatient care for women and children in LMIC, and a significant provider of reproductive and maternal health services including for inpatient care. Effective strategies and recommendations for engagement with private health providers are presented across challenges of private health provider engagement.
- Open Access
- 10 November 2022
- Published by Springer Nature in Malaria Journal
- Vol. 21 (1) , 1-8
Acceptability of pre-referral rectal artesunate for severe malaria in children under 5 years by health workers and caregivers in the Democratic Republic of the Congo, Nigeria and Uganda
For children below 6 years with suspected severe malaria attending a health care provider unable to provide parenteral malaria treatment, pre-referral rectal artesunate (RAS) is recommended by the World Health Organization to prevent death and disability. A number of African countries are in the process of rolling out quality-assured RAS for pre-referral treatment of severe malaria at community-level. The success of RAS depends, among other factors, on the acceptability of RAS in the communities where it is being rolled-out. Yet to date, there is limited literature on RAS acceptability. This study aimed to determine the acceptability of RAS by health care providers and child caregivers in communities where quality assured RAS was rolled out. This study was nested within the comprehensive multi-country observational research project Community Access to Rectal Artesunate for Malaria (CARAMAL), implemented in the Democratic Republic of the Congo (DRC), Nigeria, and Uganda between 2018 and 2020. Data from three different sources were analysed to understand RAS acceptability: interviews with health workers during three health care provider surveys (N = 341 community health workers and 467 primary health facility workers), with caregivers of children < 5 years of age during three household surveys (N = 9332 caregivers), and with caregivers of children < 5 years of age who were treated with RAS and enrolled in the CARAMAL Patient Surveillance System (N = 3645 caregivers). RAS acceptability was high among all interviewed stakeholders in the three countries. After the roll-out of RAS, 97–100% heath care providers in DRC, 98–100% in Nigeria and 93–100% in Uganda considered RAS as very good or good. Majority of caregivers whose children had received RAS for pre-referral management of severe malaria indicated that they would want to get the medication again, if their child had the same illness (99.8% of caregivers in DRC, 100% in Nigeria and 99.9% in Uganda). In three household surveys, 67–80% of caregivers whose children had not previously received RAS considered the medication as useful. RAS was well accepted by health workers and child caregivers in DRC, Nigeria and Uganda. Acceptability is unlikely to be an obstacle to the large-scale roll-out of RAS in the studied settings.
- 10 November 2022
- Published by Springer Nature in Malaria Journal
- Vol. 21 (1) , 1-8
Open AccessAcceptability of pre-referral rectal artesunate for severe malaria in children under 5 years by health workers and caregivers in the Democratic Republic of the Congo, Nigeria and Uganda
For children below 6 years with suspected severe malaria attending a health care provider unable to provide parenteral malaria treatment, pre-referral rectal artesunate (RAS) is recommended by the World Health Organization to prevent death and disability. A number of African countries are in the process of rolling out quality-assured RAS for pre-referral treatment of severe malaria at community-level. The success of RAS depends, among other factors, on the acceptability of RAS in the communities where it is being rolled-out. Yet to date, there is limited literature on RAS acceptability. This study aimed to determine the acceptability of RAS by health care providers and child caregivers in communities where quality assured RAS was rolled out. This study was nested within the comprehensive multi-country observational research project Community Access to Rectal Artesunate for Malaria (CARAMAL), implemented in the Democratic Republic of the Congo (DRC), Nigeria, and Uganda between 2018 and 2020. Data from three different sources were analysed to understand RAS acceptability: interviews with health workers during three health care provider surveys (N = 341 community health workers and 467 primary health facility workers), with caregivers of children < 5 years of age during three household surveys (N = 9332 caregivers), and with caregivers of children < 5 years of age who were treated with RAS and enrolled in the CARAMAL Patient Surveillance System (N = 3645 caregivers). RAS acceptability was high among all interviewed stakeholders in the three countries. After the roll-out of RAS, 97–100% heath care providers in DRC, 98–100% in Nigeria and 93–100% in Uganda considered RAS as very good or good. Majority of caregivers whose children had received RAS for pre-referral management of severe malaria indicated that they would want to get the medication again, if their child had the same illness (99.8% of caregivers in DRC, 100% in Nigeria and 99.9% in Uganda). In three household surveys, 67–80% of caregivers whose children had not previously received RAS considered the medication as useful. RAS was well accepted by health workers and child caregivers in DRC, Nigeria and Uganda. Acceptability is unlikely to be an obstacle to the large-scale roll-out of RAS in the studied settings.
- Open Access
- 6 September 2022
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 2 (9) , e0000464
Community access to rectal artesunate for malaria (CARAMAL): A large-scale observational implementation study in the Democratic Republic of the Congo, Nigeria and Uganda
The key to reducing malaria deaths in highly endemic areas is prompt access to quality case management. Given that many severe cases occur at peripheral level, rectal artesunate (RAS) in the form of suppositories was developed in the 1990s, allowing for rapid initiation of life-saving antimalarial treatment before referral to a health facility with full case management capabilities. One randomized controlled trial published in 2009 showed a protective effect of RAS pre-referral treatment against overall mortality of 26%, but with significant differences according to study sites and length of referral. Two important issues remained unaddressed: (1) whether the mortality impact of RAS observed under controlled trial conditions could be replicated under real-world circumstances; and (2) clear operational guidance for the wide-scale implementation of RAS, including essential health system determinants for optimal impact. From 2018 to 2020, the Community Access to Rectal Artesunate for Malaria (CARAMAL) project was conducted as a large-scale observational implementation study in the Democratic Republic of the Congo (DRC), Nigeria, and Uganda (registered on ClinicalTrials.gov as NCT03568344). CARAMAL aimed to provide high-quality field evidence on the two issues above, in three remote settings with high malaria endemicity. A number of complementary study components were implemented. The core of the CARAMAL study was the Patient Surveillance System (PSS), which allowed tracking of cases of severe febrile illness from first contact at the periphery to a referral health facility, and then on to a Day 28 visit at the home of the patient. Community and provider cross-sectional surveys complemented the PSS. Here we describe in some detail RAS implementation, as well as the key CARAMAL study components and basic implementation experience. This manuscript does not intend to present key study results, but provides an extensive reference document for the companion papers describing the impact, referral process, post-referral treatment and costing of the RAS intervention.
- 6 September 2022
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 2 (9) , e0000464
Open AccessCommunity access to rectal artesunate for malaria (CARAMAL): A large-scale observational implementation study in the Democratic Republic of the Congo, Nigeria and Uganda
The key to reducing malaria deaths in highly endemic areas is prompt access to quality case management. Given that many severe cases occur at peripheral level, rectal artesunate (RAS) in the form of suppositories was developed in the 1990s, allowing for rapid initiation of life-saving antimalarial treatment before referral to a health facility with full case management capabilities. One randomized controlled trial published in 2009 showed a protective effect of RAS pre-referral treatment against overall mortality of 26%, but with significant differences according to study sites and length of referral. Two important issues remained unaddressed: (1) whether the mortality impact of RAS observed under controlled trial conditions could be replicated under real-world circumstances; and (2) clear operational guidance for the wide-scale implementation of RAS, including essential health system determinants for optimal impact. From 2018 to 2020, the Community Access to Rectal Artesunate for Malaria (CARAMAL) project was conducted as a large-scale observational implementation study in the Democratic Republic of the Congo (DRC), Nigeria, and Uganda (registered on ClinicalTrials.gov as NCT03568344). CARAMAL aimed to provide high-quality field evidence on the two issues above, in three remote settings with high malaria endemicity. A number of complementary study components were implemented. The core of the CARAMAL study was the Patient Surveillance System (PSS), which allowed tracking of cases of severe febrile illness from first contact at the periphery to a referral health facility, and then on to a Day 28 visit at the home of the patient. Community and provider cross-sectional surveys complemented the PSS. Here we describe in some detail RAS implementation, as well as the key CARAMAL study components and basic implementation experience. This manuscript does not intend to present key study results, but provides an extensive reference document for the companion papers describing the impact, referral process, post-referral treatment and costing of the RAS intervention.